WaveMan
WaveMan · Company
IRMD · Iradimed Corp
> Search tickers & screens ⌘K
LIVE
← All companies

IRMD Iradimed (IRMD) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001325618
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
113
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · no price filed

What the filings say about IRMD

Insiders, 180 days
-$3.3M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$122.6K
1 notice

Iradimed insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, IRADIMED CORP insiders sold a net $3.3M of stock across 293 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
ALLEN MONTY K
Director
SELL
2026-09-08 SECtraded 2026-09-03
1,014
$87.7K
+2.7%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Feb 13, 2026.
  • The trade is 5.1% of the 19,986 shares held after it.
  • No other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ALLEN MONTY K sold about $87.7K of IRMD on Sep 3, 2026; 113 funds added in the latest 13F quarter.
ALLEN MONTY K
Director
SELL
2026-09-08 SECtraded 2026-09-03
405
$35.0K
+2.7%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Feb 13, 2026.
  • The trade is 2.1% of the 19,581 shares held after it.
  • No other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ALLEN MONTY K sold about $35.0K of IRMD on Sep 3, 2026; 113 funds added in the latest 13F quarter.
Scharen-Guivel Hilda Frederique
Director
SELL
2026-06-04 SEC
1,766
$167.8K
-7.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 25.8% of the 6,832 shares held after it.
  • 1 other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Scharen-Guivel Hilda Frederique sold about $167.8K of IRMD on Jun 4, 2026; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.
Scharen-Guivel Hilda Frederique
Director
SELL
2026-06-04 SEC
1,234
$117.2K
-7.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 22.0% of the 5,598 shares held after it.
  • 1 other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Scharen-Guivel Hilda Frederique sold about $117.2K of IRMD on Jun 4, 2026; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.
Susi Roger E.
CEO, President, Chairman
SELL
2026-06-02 SECtraded 2026-06-01
401
$36.5K
-5.6%
Context
  • 231 earlier Form 4 trades (code P or S) here by this insider (231 sales), the last on May 27, 2026.
  • The trade is 0.0% of the 2,163,424 shares held after it.
  • 1 other insider sold within 30 days.
  • 113 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO, President, Chairman Susi Roger E. sold about $36.5K of IRMD on Jun 1, 2026; 1 other insider sold within 30 days and 113 funds added in the latest 13F quarter.
293 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 288 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.3M over 180 days
-$122.6K over 90 days · -$2.8M of it by a 10%+ holder
below 72% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
113 funds bought in last quarter
more than 66% of Medical Devices
Revenue
+14.4% year over year
more than 59% of Medical Devices
Margin
26.8% net margin
more than 95% of Medical Devices
Buybacks
no share repurchases reported
Short interest
7.9% of the float short (float per yahoo 2026-10-26) · 4.5 days to cover · settled 2026-09-30
more than 64% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IRMD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+12.1%12M
-1%+11%+24%+37%2025-102025-122026-022026-042026-062026-082026-10 2025-12-11 · GLENN JOHN sold $1.4M2025-11-10 · GLENN JOHN sold $900.1K2026-03-06 · Susi Roger E. sold $619.0K2026-03-30 · Susi Roger E. sold $554.4K2026-03-09 · Susi Roger E. sold $500.2K2025-12-29 · Susi Roger E. sold $478.4K2026-01-12 · Susi Roger E. sold $476.2K2025-12-08 · Susi Roger E. sold $446.4K2026-01-26 · Susi Roger E. sold $436.2K2025-12-15 · Susi Roger E. sold $412.7K2025-12-22 · Susi Roger E. sold $363.7K2026-04-20 · Susi Roger E. sold $333.4K2025-10-27 · Susi Roger E. sold $329.0K2025-11-24 · Susi Roger E. sold $321.3K2025-12-01 · Susi Roger E. sold $309.0K2026-03-16 · Susi Roger E. sold $304.5K2026-05-18 · Susi Roger E. sold $301.4K2026-04-06 · Susi Roger E. sold $295.8K2026-03-23 · Susi Roger E. sold $293.8K2025-12-09 · HAWKINS JAMES B sold $289.8K2026-05-26 · Susi Roger E. sold $285.6K2026-05-12 · Susi Roger E. sold $276.8K2025-11-18 · Susi Roger E. sold $271.6K2026-03-17 · Susi Roger E. sold $256.1K2026-04-27 · Susi Roger E. sold $250.8K2026-03-10 · Susi Roger E. sold $250.3K2026-04-13 · Susi Roger E. sold $237.9K2025-11-10 · Susi Roger E. sold $235.7K2026-01-05 · Susi Roger E. sold $217.4K2026-01-20 · Susi Roger E. sold $215.1K2026-05-04 · Susi Roger E. sold $208.8K2026-03-16 · Susi Roger E. sold $202.4K2026-05-27 · Susi Roger E. sold $199.0K2026-04-14 · Susi Roger E. sold $197.4K2025-11-10 · Susi Roger E. sold $190.5K2026-01-20 · Susi Roger E. sold $184.6K2026-05-26 · Susi Roger E. sold $175.5K2026-04-13 · Susi Roger E. sold $169.6K2026-06-04 · Scharen-Guivel Hilda Frederique sold $167.8K2026-05-19 · Susi Roger E. sold $162.3K2026-03-24 · Susi Roger E. sold $158.5K2025-11-18 · Susi Roger E. sold $156.4K2026-09-03 · Monty K. Allen filed to sell $122.6K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns IRMD: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
967,825 sh
$92.5M
KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC
396,982 sh
$37.9M
RENAISSANCE TECHNOLOGIES LLC
394,412 sh
$37.7M
Copeland Capital Management, LLC
391,860 sh
$37.4M
VANGUARD CAPITAL MANAGEMENT LLC
364,937 sh
$34.9M

Congress trades in IRMD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IRMD planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Monty K. Allen
Filed 2026-09-03
$122.6K

IRMD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ranger Micro Cap Fund
$357.1K position · as of 2026-07-31
3.1%
Virtus KAR Small-Cap Growth Series
$1.0M position · as of 2026-06-30
2.2%
Virtus KAR Small-Cap Growth Fund
$13.1M position · as of 2026-06-30
2.1%
JOHNSON OPPORTUNITY FUND
$2.2M position · as of 2026-06-30
1.3%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$1.8M position · as of 2026-06-30
1.2%
M3Sixty Small Cap Growth Fund
$123.8K position · as of 2026-05-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$780.6K
$780.6K
$569.7K
+268%
n/a
2024
$689.6K
$689.6K
$825.8K
+105%
n/a
2023
$642.6K
$642.6K
$932.3K
+75%
n/a
2022
$586.0K
$586.0K
$666.7K
-37%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.3M sold by insiders over 180 days, 113 funds added last quarter, $122.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMLUNG

IRMD financials

Revenue growth
+14.4%
XBRL, annual
Net margin
26.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$86.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+26.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$25.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
+23.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+20.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
no debt line filed
Return on capital employed
+27.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
47.94x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
+2.3%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
4.57x
P/E over trailing EPS growth of 10%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$83.8M$73.2M$65.6M$53.3M
Gross profit$64.3M$56.4M$50.2M$41.3M
Operating income$26.1M$22.0M$20.0M$15.6M
Net income$22.5M$19.2M$17.2M$12.8M
EPS (diluted)1.751.501.351.02
Operating cash flow$24.9M$25.6M$13.5M$10.0M
Cash$51.2M$52.2M$49.8M$58.0M
Dividends paid$15.0M$13.7M$13.2M$12.6M
SEC XBRL, fiscal years, as known on 2026-10-27

IRMD Stock Sonar score 5/7 axes

Find similar shapesCompare

IRMD ranks highest on profitability (95th percentile) and institutional and government (66th), and lowest on insider conviction (13th), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
95
Inputs
  • Return on equity+23.5% · 91 pct, sector of 183
  • Return on assets+20.8% · 96 pct, sector of 214
  • Return on invested capitalno debt line filed
  • Return on capital employed+27.1% · 98 pct, sector of 188
Growth
59
Inputs
  • Revenue growth, YoY+14.4% · 59 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.3M · 25 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
66
Inputs
  • Funds adding, latest quarter113 · 66 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
55
Inputs
  • Short interest, % of float+7.9% · 30 pct, sector of 240
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+13.8% · 34 pct, sector of 198
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

IRMD filings, in plain words

Are Iradimed insiders buying or selling IRMD?

In the 180 days to 2026-10-27, Iradimed insiders were net sellers, a net $3.3M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of IRMD?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $122.6K of stock; the latest, by Monty K. Allen, was filed 2026-09-03.

Read the full summary

In the 180 days to 2026-10-27, Iradimed insiders were net sellers of IRMD, a net $3.3M across purchases and sales reported on Form 4 by 3 sellers. Most of that figure, $2.8M, came from a holder of 10% or more rather than an officer or director. None of the 30 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $122.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies